Arthritis Research & Therapy

Table 3 Clinical characteristics of DM patients with versus without anti-Mi-2

From: Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara

	All DM Number = 66		Mexico City DM Number = 46		Guadalajara DM Number = 20
	Anti-Mi-2 (+)	Anti-Mi-2 (-)	Anti-Mi-2 (+)	Anti-Mi-2 (-)	Anti-Mi-2 (+)	Anti-Mi-2 (-)
Number	30	36	27	19	3	17
Age	41.3	44.1	42.0	50.3	34.7	37.2
(mean ± SD)	± 14.2	± 16.3	± 14.7^a	± 15.1^{a, b}	± 4.5	± 15.3^b
% male	37%	22%	33%	26%	67%	18%
Shawl sign	86%^c	61%^c	85%	78%^d	100%	40%^d
Heliotrope	74%	79%	71%	89%	100%	69%
Gottrön	78%	74%	79%	78%	67%	69%
Malignancy	0%	6%	0%	11%	0%	0%
Fever	30%	25%	25%	28%	67%	21%
Calcinosis	7%	9%	4%	5%	33%	13%
ILD	7%	9%	4%	17%	50%	0%
Initial CPK IU/L (mean ± SD)	5,369 ± 4,124^e	2,860 ± 5,183^e	4,800 ± 3,111^f	3,502 ± 6,068^{f, g}	NA	1,808 ± 3,475^g
Initial CPK < 200 IU/L	0%^h	34%^h	0%ⁱ	22%^{i, j}	NA	55%^j
Initial CPK > 1,000 IU/L	100%^k	52%^k	100%^l	67%^{l, m}	NA	27%^m
Initial CPK > 5,000 IU/L	54%ⁿ	14%ⁿ	52%^o	17%^o	NA	9%
Last CPK > 500 IU/L	37%^p	7%^p	15%	0%	NA	18%
Last CPK < 200 IU/L	45%	69%	45%	67%	NA	73%

^aP < 0.05; ^bP < 0.005; ^cP < 0.05; ^dP < 0.05; ^eP < 0.0005; ^fP < 0.01; ^gnot significant; ^hP < 0.005; ⁱP < 0.05; ^jP = 0.11; ^kP < 0.0001; ^lP < 0.005; ^mP = 0.06; ⁿP < 0.005; 15, ^oP < 0.05; ^pP = 0.095. CPK, creatine phosphokinase; DM, dermatomyositis; ILD, interstitial lung disease; NA, not applicable (due to small numbers).

Back to article page

ISSN: 1478-6362

Contact us

General enquiries: journalsubmissions@springernature.com